Human VEGF-D Quantikine ELISA Kit | R&D Systems DVED00 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

ELISA/assay

product name :

Human VEGF-D Quantikine ELISA Kit

catalog :

DVED00

quantity :

1 Kit

price :

655 USD

citations: 36

Reference
Chachaj A, Stanimirova I, Chabowski M, Gomu x142 kiewicz A, Hodurek P, Glatzel Pluci x144 ska N, et al. Sodium accumulation in the skin is associated with higher density of skin lymphatic vessels in patients with arterial hypertension. Adv Med Sci. 2023;68:276-289 pubmed publisher
Fornaro L, Musettini G, Orlandi P, Pecora I, Vivaldi C, Banchi M, et al. Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer. Am J Cancer Res. 2022;12:3347-3356 pubmed
Wada I, Nakao S, Yamaguchi M, Kaizu Y, Arima M, Sawa S, et al. Retinal VEGF-A Overexpression Is Not Sufficient to Induce Lymphangiogenesis Regardless of VEGF-C Upregulation and Lyve1+ Macrophage Infiltration. Invest Ophthalmol Vis Sci. 2021;62:17 pubmed publisher
Wyatt M, Baumgarten S, Weaver A, Van Oort C, Fedyshyn B, Ruano R, et al. Evaluating Markers of Immune Tolerance and Angiogenesis in Maternal Blood for an Association with Risk of Pregnancy Loss. J Clin Med. 2021;10: pubmed publisher
Mashima T, Wakatsuki T, Kawata N, Jang M, Nagamori A, Yoshida H, et al. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo. Sci Rep. 2021;11:15125 pubmed publisher
Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, et al. Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease. J Am Heart Assoc. 2020;9:e015761 pubmed publisher
Chin T, Lin C, Chang S, Wang H, Huang H, Soong Y, et al. Application of non-invasive detection of peripheral vascular dysfunction in ovarian hyperstimulation syndrome (OHSS): A pilot study of clinical relevance. Taiwan J Obstet Gynecol. 2019;58:354-358 pubmed publisher
Hirose M, Matsumuro A, Arai T, Sugimoto C, Akira M, Kitaichi M, et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS ONE. 2019;14:e0212776 pubmed publisher
Chebib N, Archer F, Bobet Erny A, Leroux C, Cottin V. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration. Sci Rep. 2018;8:14698 pubmed publisher
Nascimento E, Baldi B, Mariani A, Annoni R, Kairalla R, Pimenta S, et al. Immunohistological features related to functional impairment in lymphangioleiomyomatosis. Respir Res. 2018;19:83 pubmed publisher
Kumar N, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, et al. Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J Infect. 2017;74:10-21 pubmed publisher
Chou C, Modo M. Human neural stem cell-induced endothelial morphogenesis requires autocrine/paracrine and juxtacrine signaling. Sci Rep. 2016;6:29029 pubmed publisher
Kumar N, Banurekha V, Nair D, Babu S. Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE. 2016;11:e0146318 pubmed publisher
Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla Herttuala S, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer. 2014;14:696 pubmed publisher
Weinkopff T, Mackenzie C, Eversole R, Lammie P. Filarial excretory-secretory products induce human monocytes to produce lymphangiogenic mediators. PLoS Negl Trop Dis. 2014;8:e2893 pubmed publisher
Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, et al. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res. 2014;74:873-83 pubmed publisher
Braicu E, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, et al. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin an. Cytokine. 2013;61:755-8 pubmed publisher
Majumder M, Tutunea Fatan E, Xin X, Rodriguez Torres M, Torres Garcia J, Wiebe R, et al. Co-expression of ?9?1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. PLoS ONE. 2012;7:e35094 pubmed publisher
Chang W, Cane J, Blakey J, Kumaran M, Pointon K, Johnson S. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res. 2012;13:34 pubmed publisher
Dabora S, Franz D, Ashwal S, Sagalowsky A, DiMario F, Miles D, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE. 2011;6:e23379 pubmed publisher
Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F, et al. Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res. 2011;31:2589-95 pubmed
Konings I, de Jonge M, Burger H, van der Gaast A, van Beijsterveldt L, Winkler H, et al. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br J Cancer. 2010;103:987-92 pubmed publisher
Honda N, Jinnin M, Kajihara I, Makino T, Fukushima S, Ihn H. Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis. Br J Dermatol. 2010;163:776-80 pubmed publisher
Papiewska Pajak I, Boncela J, Przygodzka P, Cierniewski C. Autocrine effects of VEGF-D on endothelial cells after transduction with AD-VEGF-D(DeltaNDeltaC). Exp Cell Res. 2010;316:907-14 pubmed publisher
Glasgow C, Avila N, Lin J, Stylianou M, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest. 2009;135:1293-1300 pubmed publisher
Toivanen P, Nieminen T, Viitanen L, Alitalo A, Roschier M, Jauhiainen S, et al. Novel vascular endothelial growth factor D variants with increased biological activity. J Biol Chem. 2009;284:16037-48 pubmed publisher
Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, et al. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol. 2008;36:1035-46 pubmed publisher
Simiantonaki N, Jayasinghe C, Michel Schmidt R, Peters K, Hermanns M, Kirkpatrick C. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int J Oncol. 2008;32:585-92 pubmed
Koponen J, Kekarainen T, E Heinonen S, Laitinen A, Nystedt J, Laine J, et al. Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Mol Ther. 2007;15:2172-7 pubmed
Lee C, Tien H, Hu C, Chou W, Lin L. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br J Cancer. 2007;97:877-82 pubmed
Kholova I, Koota S, Kaskenpää N, Leppänen P, Narvainen J, Kavec M, et al. Adenovirus-mediated gene transfer of human vascular endothelial growth factor-d induces transient angiogenic effects in mouse hind limb muscle. Hum Gene Ther. 2007;18:232-44 pubmed
Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007;67:593-9 pubmed
Kummel S, Eggemann H, Luftner D, Thomas A, Jeschke S, Zerfel N, et al. Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes. Anticancer Res. 2006;26:1719-26 pubmed
Akahane M, Akahane T, Shah A, Okajima E, Thorgeirsson U. A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells. Anticancer Res. 2005;25:701-7 pubmed
Fink A, Kaltenegger I, Schneider B, Fruhauf J, Jurecka W, Steiner A. Serum level of VEGF-D in patients with primary lymphedema. Lymphology. 2004;37:185-9 pubmed
George M, Tutton M, Janssen F, Arnaout A, Abulafi A, Eccles S, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 2001;3:420-7 pubmed

product information

master code :

DVED00

SKU :

DVED00

product name :

Human VEGF-D Quantikine ELISA Kit

unit size :

1 Kit

description :

The Human VEGF-D Quantikine ELISA Kit from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human VEGF-D in cell culture supernates (50 ul), serum (50 ul), edta plasma (50 ul), heparin plasma (50 ul).

target :

VEGF-D

category :

ELISAs

species :

Human

specificity :

Natural and recombinant human VEGF-D

gene symbol :

FIGF

kit type :

Solid Phase Sandwich ELISA

assay length :

4.5 hours

elisaSampleTypes :

Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL)

elisaSensitivity :

31.3 pg/mL

elisaRange :

125.00 - 4000 pg/mL

Antibody validation :

Knockout/Knockdown

top caption :

Human VEGF-D ELISA Cell Culture Supernate Standard Curve

applications :

ELISA

USD :

655 USD

product details :

The Quantikine Human VEGF-D Immunoassay is a 4.5 hour solid phase ELISA designed to measure VEGF-D levels in cell culture supernates, serum, and plasma. It contains Sf 21-expressed, recombinant human VEGF-D and antibodies raised against the recombinant protein. Results obtained for naturally occurring human VEGF-D showed linear curves that were parallel to the standard curves obtained using the kit standards. These results indicate that this kit can be used to determine relative mass values for natural human VEGF-D.

alt names :

c-fos induced growth factor (vascular endothelial growth factor D), FIGF, vascular endothelial growth factor D, VEGFD, VEGF-DVEGFDc-Fos-induced growth factor

storage :

Store the unopened product at 2 - 8 ░C. Do not use past expiration date.